A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis

Merck Sharp & Dohme LLC18 enrolled

Overview

The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.

In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Candidiasis, Esophageal HIV Infections

Interventions

L-743,872DRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria You may be eligible for this study if you: * Are an 18- to 65-year-old man with candidal esophagitis.

Locations (1)

Gary Calandra

Rahway, New Jersey, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.